Treatment of periodontal defects with a combination of autologous blood products and antibiotics
Phase 2
- Conditions
- Health Condition 1: K053- Chronic periodontitis
- Registration Number
- CTRI/2024/07/070193
- Lead Sponsor
- DOGIPARTHI MOUNICA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Periodontitis patients with the presence of intra-bony defect (IBD) =3 mm deep (distance between alveolar crest and base of the defect) on an intraoral periapical radiograph [IOPA].
2.Interproximal probing depth (PD) =5 mm after phase I therapy in asymptomatic maxillary/ mandibular molar teeth.
Exclusion Criteria
1.Patients with systemic conditions known to affect the periodontal status.
2.Patients taking medications known to affect the outcomes of periodontal therapy.
3.Pregnant and lactating women.
4.Teeth with furcation defects, non-vital teeth, and mobility of at least grade II.
5.History of periodontal surgery in past one year.
6.Patients with unacceptable oral hygiene.
7.Smokers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Linear bone growth <br/ ><br>2.Wound healing indexTimepoint: 10 days, 1 month, 6 months, 9 months
- Secondary Outcome Measures
Name Time Method 1.Probing depth reduction <br/ ><br>2.Relative attachment level gain <br/ ><br>3.Full mouth bleeding scores <br/ ><br>4.Full mouth plaque scores <br/ ><br>5.Modified gingival index <br/ ><br>6.Gingival margin position <br/ ><br>7.Alveolar crest positionTimepoint: Baseline, 3, 6 and 9 months